Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.

Van Cutsem E, Bang YJ, Mansoor W, Petty RD, Chao Y, Cunningham D, Ferry DR, Smith NR, Frewer P, Ratnayake J, Stockman PK, Kilgour E, Landers D.

Ann Oncol. 2017 Jun 1;28(6):1316-1324. doi: 10.1093/annonc/mdx107.

PMID:
29177434
2.

A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.

Paik PK, Shen R, Berger MF, Ferry D, Soria JC, Mathewson A, Rooney C, Smith NR, Cullberg M, Kilgour E, Landers D, Frewer P, Brooks N, André F.

Clin Cancer Res. 2017 Sep 15;23(18):5366-5373. doi: 10.1158/1078-0432.CCR-17-0645. Epub 2017 Jun 14.

3.

Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor.

Dickinson PA, Cantarini MV, Collier J, Frewer P, Martin S, Pickup K, Ballard P.

Drug Metab Dispos. 2016 Aug;44(8):1201-12. doi: 10.1124/dmd.115.069203. Epub 2016 May 25.

PMID:
27226351
4.

Decision-making in early clinical drug development.

Frewer P, Mitchell P, Watkins C, Matcham J.

Pharm Stat. 2016 May;15(3):255-63. doi: 10.1002/pst.1746. Epub 2016 Mar 17.

PMID:
26991401
5.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M.

N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.

6.

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

Balmaña J, Tung NM, Isakoff SJ, Graña B, Ryan PD, Saura C, Lowe ES, Frewer P, Winer E, Baselga J, Garber JE.

Ann Oncol. 2014 Aug;25(8):1656-63. doi: 10.1093/annonc/mdu187. Epub 2014 May 14.

PMID:
24827126
7.

Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group.

N Engl J Med. 2008 Mar 20;358(12):1215-28. doi: 10.1056/NEJMoa070812. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530.

8.

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study.

Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, Grosset DG, Arnold G, Leenders KL, Hundemer HP, Lledó A, Wood A, Frewer P, Schwarz J.

Mov Disord. 2006 Mar;21(3):343-53.

PMID:
16211594
9.

The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment.

Haro JM, Edgell ET, Frewer P, Alonso J, Jones PB; SOHO Study Group.

Acta Psychiatr Scand Suppl. 2003;(416):7-15.

PMID:
12755849
10.

Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients.

Attanasio AF, Howell S, Bates PC, Frewer P, Chipman J, Blum WF, Shalet SM.

J Clin Endocrinol Metab. 2002 Jul;87(7):3368-72.

PMID:
12107251
11.

Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms.

Kehely A, Bates PC, Frewer P, Birkett M, Blum WF, Mamessier P, Ezzat S, Ho KK, Lombardi G, Luger A, Marek J, Russell-Jones D, Sönksen P, Attanasio AF.

J Clin Endocrinol Metab. 2002 May;87(5):1974-9.

PMID:
11994327
12.

Confirmation of severe GH deficiency after final height in patients diagnosed as GH deficient during childhood.

Attanasio AF, Howell S, Bates PC, Blum WF, Frewer P, Quigley C, Shalet SM.

Clin Endocrinol (Oxf). 2002 Apr;56(4):503-7.

PMID:
11966743

Supplemental Content

Loading ...
Support Center